Cellaviva becomes an independent company under NextCell Pharma

June 5, 2024

Cellaviva, the stem cell bank operated by NextCell Pharma AB, has announced its transition to an independent company. This strategic move will enable Cellaviva to further focus on its core mission of providing expectant parents with the opportunity to preserve and store valuable stem cells collected from the placenta and umbilical cord. These cells, which would otherwise be discarded post-birth, offer significant potential for future medical treatments and therapies.

Since its inception in August 2015, Cellaviva has garnered a growing customer base each year, reflecting increasing awareness and demand for stem cell preservation services. This growth trajectory has positioned Cellaviva to successfully operate as a separate limited company effective September 1, 2024, while remaining a wholly owned subsidiary of NextCell Pharma AB.

Incoming CEO of Cellaviva Sofie Falk Jansson will outline her vision and strategic plans for the company's future in a presentation scheduled for 09:00 today, Wednesday, June 5. The presentation will be available for live streaming and for later viewing via the provided link:

https://www.redeye.se/events/1014540/investor-update-nextcell-pharma

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase 3 study. ProTrans is manufactured utilizing the patented platform technology for selection of optimal cells with potency to treat inflammatory disorders including autoimmune diseases. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up.

Download attachment Read full press release on Cision (external link)

2025-03-13

Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv

NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12–21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month follow-up. The collected data is currently being compiled, and an administrative subgroup analysis is planned to be presented at the IDF World Diabetes Congress in Bangkok from April 7–10.

Read more Read more

2025-02-19

All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study

NextCell Pharma AB ("NextCell") announced today that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, have been treated. The study is being conducted at Örebro University Hospital and includes a total of nine patients, with three patients in each dose group.

Read more Read more

2025-01-30

NextCell Pharma publish Interim Report 1 2024/2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2024-12-17

Long-term Effects with Repeated ProTrans Treatment After 6 Years

NextCell Pharma AB reports new results from the ProTrans-Repeat study, where type 1 diabetes patients have been followed for 5 years after receiving two doses of the stromal cell product ProTrans, in total 6 years after the first infusion. The results show that two out of three patients in the high-dose group increased their insulin production by 23% and 34% respectively.

Read more Read more

2024-12-05

NextCell Pharma changes Certified Adviser to Redeye AB

NextCell Pharma has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on January 1, 2025.

Read more Read more

2024-11-25

QVance’s Partnerships Driving Innovation in Advanced Therapies

NextCell Pharma AB*, parent company of QVance, proudly supports QVance’s newly announced partnership with Royale International. This collaboration, which combines Royale International’s global expertise in logistics with QVance’s innovative quality control solutions, strengthens the supply chain for cell and gene therapies across Europe.

Read more Read more

2024-11-18

QVance Announces Partnership

NextCell Pharma AB* comments on its subsidiary QVance’s partnership with bioMérieux Sweden AB, which aims to strengthen quality control analytics for cell and gene therapy products in the Nordic region. The collaboration will enhance QVance’s capacity to provide microbiological testing for advanced therapies.

Read more Read more

2024-11-08

QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT

NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article in collaboration with the International Society of Cell and Gene Therapy (ISCT). The article, authored by Dr. Lindsay Davies, CSO at NextCell and co-founder of QVance, was published in Cytotherapy and is based on a global survey examining knowledge on particulates in cell and gene therapy (CGT) products.

Read more Read more